Therapeutics Using Adipose Cells and Cell Secretions

Abstract

The invention relates to compositions comprising (i) adipose tissue-derived cell secretions or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, and to their use in pharmaceutical compositions and methods for treatment of various conditions. The invention also relates to improved methods, agents and compositions for cryopreservation of cells.

1 .- 60 . (canceled) 
     
     
         61 . A method of alleviating pain in a mammalian subject, the method comprising, administering to the subject a pharmaceutical composition which comprises adipose tissue-derived cell secretions, wherein said adipose tissue-derived cell secretions are prepared by culturing multiply-passaged adherent progeny cells from an adipose tissue-derived cell suspension and harvesting supernatant from the cell culture after about 3 or more days, said adherent progeny cells having a fibroblast-like appearance. 
     
     
         62 . The method according to  claim 61 , wherein said administration to said subject is by intra-articular injection or by intramuscular injection or by subcutaneous injection or by topical administration. 
     
     
         63 . The method according to  claim 61 , wherein the pain is back pain, or is pain associated with a burn injury, an inflammatory disorder, a ligament injury, a tendon injury, or the sciatic nerve, or is neuropathic pain. 
     
     
         64 . The method according to  claim 63 , wherein the neuropathic pain is facial pain, pain of the teeth, jaw, gum or of a limb. 
     
     
         65 . The method according to  claim 61 , wherein the adipose tissue-derived cell suspension (i) comprises adipocytes or (ii) is substantially free of adipocytes. 
     
     
         66 . The method according to  claim 61 , wherein the subject is selected from the group consisting of (i) a human, (ii) poultry, (iii) an equine animal, (iv) a feline animal, (v) a canine animal, (vi) a bovine animal, and (vii) a porcine animal. 
     
     
         67 . The method according to  claim 61 , wherein the adipose tissue-derived cell secretions or the adipose tissue-derived cell suspension is (i) derived from adipose tissue allogeneic to the recipient subject or animal, or (ii) derived from the intended recipient subject or animal, or (iii) derived from adipose tissue xenogeneic to the recipient subject or animal. 
     
     
         68 . The method according to  claim 61 , wherein the adipose tissue-derived cell secretions is a preparation concentrated by between 2-fold and 20-fold. 
     
     
         69 . The method according to  claim 61 , wherein said adipose tissue-derived cell secretions comprises concentrated media from culture of an adipose tissue-derived cell suspension, optionally wherein said adipose tissue-derived cell suspension (i) comprises adipocytes and adipose tissue-derived mesenchymal stem cells or (ii) is substantially free of adipocytes, optionally wherein said media from culture of an adipose tissue-derived cell suspension is concentrated between 2-fold and 20-fold. 
     
     
         70 . A kit comprising (a) a pharmaceutical composition comprising adipose tissue-derived cell secretions from an adipose tissue-derived cell suspension, wherein said adipose tissue-derived cell secretions are prepared by culturing multiply-passaged adherent progeny cells from an adipose tissue-derived cell suspension and harvesting supernatant from the cell culture after about 3 or more days, said adherent progeny cells comprising cells having a fibroblast-like appearance; and (b) instructions for use of said kit in alleviating pain in a mammalian subject. 
     
     
         71 . The kit according to  claim 70 , wherein the pain is back pain, or is pain associated with a burn injury, an inflammatory disorder, a ligament injury, a tendon injury, or the sciatic nerve, or is neuropathic pain, optionally wherein the neuropathic pain is facial pain, pain of the teeth, jaw, gum or of a limb. 
     
     
         72 . The kit according to any  claim 70 , wherein the adipose tissue-derived cell suspension (i) comprises adipocytes, or (ii) is substantially free of adipocytes. 
     
     
         73 . The kit according to  claim 70 , wherein the adipose tissue-derived cell secretions is (i) derived from adipose tissue allogeneic to the recipient subject or animal, or (ii) derived from the intended recipient subject or animal, or (iii) derived from adipose tissue xenogeneic to the recipient subject or animal. 
     
     
         74 . The kit according to  claim 70 , wherein the adipose tissue-derived cell secretions is a preparation concentrated by between 2-fold and 20-fold. 
     
     
         75 . The kit according to  claim 70 , wherein said adipose tissue-derived cell secretions comprises concentrated media from culture of an adipose tissue-derived cell suspension, optionally wherein said adipose tissue-derived cell suspension (i) comprises adipocytes and adipose tissue-derived mesenchymal stem cells or (ii) is substantially free of adipocytes, optionally wherein said media from culture of an adipose tissue-derived cell suspension is concentrated between 2-fold and 20-fold.